• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Novel basically substituted 5-halothienoisothiazole- 3(2H)-one-1,1-dioxides of the formula …<IMAGE>… in which… R1 represents hydrogen, (C1-C4)-alkyl or halogen,… R2 represents halogen and… n represents an integer from 2 to 6, their pharmaceutically tolerable acid addition salts, a process for their preparation and their use in medicaments for the treatment of anxiety states.
    公开号:SU1729293A3
    申请号:SU894613473
    申请日:1989-02-17
    公开日:1992-04-23
    发明作者:Биндер Дитер；Ровенсцки Франц
    申请人:Хемиш Фармацойтише Форшунгсгезельшафт Мбх (Фирма)；
    IPC主号:
    专利说明:

    This invention relates to a process for the preparation of new derivatives of 5-haloethenoisothiazol-3 (2H) -one-1,1-dioxides of the general formula

    Oh oh
    H
    4- (1-piperazinyl) -butyl-but-but- or benzoisothiazol-3 (2H) -ones unsubstituted by 5-halogen on the thiophenic ring and also have an anxiolytic effect are known.
    The purpose of the invention is to obtain new ythyenoisothiazol-3 (2H) -one, which are more active than the known structural analogues. The compound of general formula p
    V
    , $ x and-number
    vj Yu 4D Yu Yu SO

    CJ
    X is halogen
    is reacted with 1- (2-pyrimidinyl) piperazine in absolute dimethylformamide at 60 ° C for 45 minutes, followed by isolation of the desired product in the free state or as a pharmaceutically tolerable acid addition salt.
    EXAMPLE 1. 5 Chloro-2 {4-4- (2-pyridinidyl) -1-piperazinyl butyl} thieno (2,3-c) isothiazol-3 (2H) -one-1 , 1-Dioxide ..
    5.5 g (13.6 mmol) of 2- (4-iodobutyl) -5-chlorothieno (2,3-b) isothiazol-3 (2H) -one-1,1-dioxide are mixed with 25 ml of absolute dimethylformamide and heat the solution to 40 ° C. 2.23 g (13.6 mmol) of 1- (2-pyrimidinyl) piperazine are then dissolved in absolute dimethylformamide at 60 ° C and dropped in for 1 minute. After 45 minutes, the solvent is evaporated at 60 ° C and the oily orange residue is taken up in 25 ml of methylene chloride. The methylene chloride phase is extracted by shaking 2 more times, each time with 20 ml of water, and then 8 times with a total of 130 ml of 2N. hydrochloric acid. The acidic, aqueous phase is neutralized with solid sodium bicarbonate (pH 7.5) and then extracted 4 times with shaking, each time with 25 ml of methylene chloride. The combined organic phases are dried over sodium sulfate, filtered and evaporated. The resulting crude product (4.0 g, 57% of theory) is dissolved in 45 ml of isopropanol at the boiling point and a little insoluble by-product (70 mg) is filtered off in a hot state. The mother liquor is crystallized in a low-temperature refrigerator with repeated trituration, then the yellow product is filtered under suction and three times digested with cold, like ice, isopropanol. The resulting crude product (3.3 g, 7.67 mmol) is dissolved in 35 ml of acetone at boiling temperature, filtered and after cooling, mixed with 0.93 g (7.67 mmol) of a 29.2% solution hydrochloric acid in methanol. The hydrochloride is crystallized in a low-temperature refrigerator with repeated trituration, sucked off and digested three times with a small amount of cold, like ice, acetone. Dried at 40 ° C and 20 mbar, 2.93 g of hydrochloride are suspended in 45 ml of water, brought to pH 7.5 with a saturated solution of sodium bicarbonate and extracted 4 times with 30 ml of methylene chloride each time. The combined organic phases are dried over sodium sulfate, mixed with active carbon, filtered and evaporated (2.75 g).
    The final purification was performed by column chromatography (KG 60, 50: 1, the solvent was diethyl ether). The product is recrystallized again in 25 ml of isopropanol.
    Yield 2.25 g of slightly yellow crystals (38% of theory). M.p. 134-135.5 ° C (isopropanol).
    Calculated,%: C 46.20; H 4.56; N 15.85.
    0
    С17Н2оМ5СЮз52 (mol.m. 441.96;
    Found,%: C 46.04; H 4.62; N 15.70. 1 H-NMR (nuclear magnetic resonance), C, b, ppm: 8.29 (d, J 4.9 Hz, 2H, Rug-H4 and H6 (7.28) S, 1H, Ti-He); 6.47 (t, J 4.9 Hz, 1H,
    5 Pyr-Hs); 3.90-3.70 (t, 6H, Pip-Hz and Hs, TI-CH2-); 2.56-2.36 (m, 6H, Plp-bfc, and He, -CH2-Pip); 2.00-1.50 (t, 4H, Ti-C-CH2- and -CH2-C-PIP-).
    Preparation of the starting material 2- (40 bromobutyl) -5-chlorothieno (2,3-c)) isothiazol-3 (2H) -one-1,1-dioxide.
    15 g (67.1 mmol) of 5-chlorothieno (2,3-d) nso-thiazol-3 (2H) -one-1,1-dioxide are dissolved in 100 ml of absolute dimethylformamide.
    5 Then, 2.82 g (70.5 mmol) of the 60% sodium hydride suspension are washed 4 times with absolute benzene and slowly added with ice-cooling and strong magnetic stirring to the dimethylformamide solution so that the temperature does not rise above 15 ° C . After stirring for 15 minutes at room temperature, the reaction mixture is heated to 60 ° C and mixed for 43 min with 43.5 g
    5 (202 mmol) 1,4-dibromobutane. After 3 hours at 60 ° C, the solution is evaporated at 70 ° C and 1.5 mbar. The remaining yellow oil is suspended in 40 ml of saturated sodium bicarbonate solution and extracted three times,
    0 each time with 50 ml of methylene chloride. The combined organic phases are then extracted by shaking twice, each time with 50 ml of saturated sodium bicarbonate solution, and twice with only 110
    5 ml of water. The organic phase is dried over sodium sulfate, mixed with active carbon, filtered and evaporated. The crude product is dissolved in 100 ml of diethyl ether at the boiling point and
    50 mg of a colorless by-product are sucked off. After evaporation of the solvent, 19.74 g of solid crude product remain, which can be used without further purification in the next reaction step. 0.7 g
    5 is subjected to purification by chromatography on a column (KG 60, 40: 1, the solvent is methylene chloride, yield 0.62 g).
    Output 17.48 g of colorless crystals (73% of theory). M.p. 75-76 ° C (diethyl ether).
    interact with 1- (2-pyrimidinyl) piperazine in absolute dimethylformamide at 60 ° C for 45 minutes, followed by isolation of the target
    product in its free state or in the form of a pharmaceutically tolerable acid addition salt.
    权利要求:
    Claims (1)
    [1]
    Claim
    The method of obtaining derivatives of 5-halothienoisothiazole-3 (2 N) -one-1,1-dioxides of the General formula
    0 0.
    where Ri is a halogen, where are their pharmaceutically tolerable acid addition salts, wherein the compound of general formula
    About where Ri - has the indicated meaning. X is a halogen, is reacted with 1- (2-pyrimidinyl) piperazine in absolute dimethylformamide at 60 ° C for 45 minutes, followed by isolation of the target product in a free state or in the form of a pharmaceutically acceptable acid addition salt,
    类似技术:
    公开号 | 公开日 | 专利标题
    AU2003265585B2|2008-07-03|Calcium receptor modulating compound and use thereof
    PL69767B1|1973-08-31|11-substituted 5 11-dihydro-6h-pyrido|benzodiazepin-6-ones [us3660380a]
    EP0091241A2|1983-10-12|Condensed pyrrolinone derivatives, and their production
    EP0508549A2|1992-10-14|New triazolopyrimidine and pyrazolopyrimidine derivatives useful for treating cachexia
    EP0104522B1|1991-05-29|New pyrazolo|pyridine derivatives and process for producing them
    SU1729293A3|1992-04-23|Method for preparation derivatives of 5-haloid tienoisothiazole-3 |-oh-1,1 dioxides
    US4236004A|1980-11-25|2-Alkylsulphonyl-7,8-dihydro-5-hydroxy-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives
    Landreau et al.2002|Efficient regioselective synthesis of triheterocyclic compounds: imidazo [2, 1-b] benzothiazoles, pyrimido [2, 1-b] benzothiazolones and pyrimido [2, 1-b] benzothiazoles
    SU474981A3|1975-06-25|The method of obtaining 9 | -thioxanthenes or their salts
    US4213985A|1980-07-22|Novel 5,11-dihydro-6H-pyrido-[2,3-b][1,4]-benzodiazepine-6-ones
    SU668609A3|1979-06-15|Method of obtaining derivatives of 5-piperazinopyrido|-benzothiazepine
    SU1549480A3|1990-03-07|Method of producing derivatives of iminothiazolidine or their hydrochlorides
    SU1042620A3|1983-09-15|Process for preparing substituted n-|-1-keto-1h-triazole | pyrimidine-2-carboxamides or their salts |
    US4108894A|1978-08-22|Amidines
    US4301281A|1981-11-17|7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]-pyrimidine-6-carboxylic acid amides
    IE46258B1|1983-04-20|11-oxo-ii-|-pyrido|quinazolines
    RU1838309C|1993-08-30|Method of synthesis of quinazoline derivatives or their pharmaceutically acceptable acid-additive salts
    SU584782A3|1977-12-15|Method of preparing aminoimidazoisoquinoline derivatives or salts thereof
    KR20020052213A|2002-07-02|Process for the preparation of 6-methyl-2-|-imidazo[1,2-a]pyrimidine-3-| and intermediates
    US4118501A|1978-10-03|Thiazolidine derivatives
    EP0294615B1|1992-04-15|Cyclobutene-3,4-dione-intermediates and their use in the preparation of histamine h2-antagonists
    SU1181546A3|1985-09-23|Method of producing condensed pyrimidine derivatives as racemates or optical isomers
    US5952494A|1999-09-14|Method for the preparation of pyrido benzoxazine derivatives
    US4156735A|1979-05-29|Thiazolidine derivatives
    SU1028248A3|1983-07-07|Process for preparing substituted pyrazolobenzodiazepines or their acid addition salts
    同族专利:
    公开号 | 公开日
    UA13481A|1997-04-25|
    NZ227939A|1991-02-26|
    DE58907804D1|1994-07-14|
    EP0328913B1|1994-06-08|
    PH26156A|1992-03-18|
    CN1024798C|1994-06-01|
    NO176050B|1994-10-17|
    SI8910358A|1997-02-28|
    MY103825A|1993-09-30|
    IL89185D0|1989-09-10|
    ES2054887T3|1994-08-16|
    CA1317956C|1993-05-18|
    HRP940825A2|1996-04-30|
    DK73289A|1989-10-11|
    FI89491C|1993-10-11|
    ATA39088A|1990-06-15|
    FI890690A0|1989-02-14|
    KR890013033A|1989-09-21|
    AT106888T|1994-06-15|
    NO176050C|1995-01-25|
    CN1038646A|1990-01-10|
    EG20261A|1998-05-31|
    CS93189A2|1990-10-12|
    JPH01249779A|1989-10-05|
    LTIP1813A|1995-08-25|
    LT3947B|1996-05-27|
    CS274578B2|1991-08-13|
    DD279021A5|1990-05-23|
    HUT50839A|1990-03-28|
    US4929616A|1990-05-29|
    IL89185A|1992-08-18|
    FI890690A|1989-08-19|
    EP0328913A2|1989-08-23|
    AU2994589A|1989-08-24|
    ZA891108B|1989-10-25|
    EP0328913A3|1991-01-23|
    YU35889A|1990-06-30|
    DK170047B1|1995-05-08|
    FI89491B|1993-06-30|
    NO890691L|1989-08-21|
    AU618577B2|1992-01-02|
    HU201084B|1990-09-28|
    NO890691D0|1989-02-17|
    DK73289D0|1989-02-17|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    IL47877A|1974-08-26|1978-10-31|Sparamedica Ag|Thienothiazine carboxamide derivatives,their manufacture and pharmaceutical compositions containing them|
    DE2534689C3|1974-09-16|1979-10-18|Basf Ag, 6700 Ludwigshafen|
    LU78009A1|1977-08-22|1979-05-23|Hoffmann La Roche|METHOD FOR PRODUCING THIAZINE DERIVATIVES|
    AU518216B2|1977-09-06|1981-09-17|Hafslund Nycomed Pharma Aktiengesellschaft|Thienothiazine derivatives|
    DE2749640A1|1977-11-05|1979-05-10|Thomae Gmbh Dr K|Furo and thieno -isothiazole-3-one-1,1-di:oxide - artificial sweetening agents with high activity and low toxicity and side effects|
    AT364852B|1977-11-05|1981-11-25|Thomae Gmbh Dr K|METHOD FOR PRODUCING CONDENSED ISOTHIAZOL-3 -ON-1,1-DIOXIDES AND THEIR SALTS|
    DE2839266A1|1978-09-09|1980-03-20|Thomae Gmbh Dr K|Furo and thieno -isothiazole-3-one-1,1-di:oxide - artificial sweetening agents with high activity and low toxicity and side effects|
    DE3371082D1|1982-09-09|1987-05-27|Hoffmann La Roche|THIENO -1,2-THIAZINE DERIVATIVES|
    DE3321969A1|1983-06-18|1984-12-20|Troponwerke GmbH & Co KG, 5000 Köln|2-PYRIMIDINYL-1-PIPERAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THE SAME|
    FI862513A|1985-07-04|1987-01-05|Chemie Linz Ag|NYA TIENO-1,2-THIAZOLDERIVAT, FOERFARANDE FOER DERAS FRAMSTAELLNING OCH DESSA INNEHAOLLANDE PHARMACEUTICAL PREPARAT.|
    US4675403A|1985-10-16|1987-06-23|American Home Products Corporation|3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity|
    US4732984A|1985-10-17|1988-03-22|American Home Products Corporation|Piperazinoisothiazolones with psychotropic activity|DE68918832T2|1988-12-28|1995-02-09|Suntory Ltd|Benzoxazepine derivatives.|
    ES2777924T3|2004-05-23|2020-08-06|Hmi Medical Innovations Llc|Teramutein modulators|
    US8431110B2|2005-05-23|2013-04-30|Hmi Medical Innovations, Llc.|Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators|
    JP2009523408A|2005-11-23|2009-06-25|ジェラルド・エム・ハウシー|Group of compounds and methods for identifying, synthesizing, optimizing and analyzing protein modulators|
    CN101186612B|2006-11-15|2012-10-03|天津和美生物技术有限公司|Pyrroline derivative capable of inhibiting cell to release tumor necrotic factor and its preparation and application|
    US8551560B2|2008-05-23|2013-10-08|Intermolecular, Inc.|Methods for improving selectivity of electroless deposition processes|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    AT88390A|ATA39088A|1988-02-18|1988-02-18|BASICALLY SUBSTITUTED THIENOISOTHIAZOL-3-ON-1,1-DIOXIDES AND THEIR PHARMACEUTICALLY COMPATIBLE SALTS, METHOD FOR THE PRODUCTION AND THEIR USE|LV931251A| LV5521A3|1988-02-18|1993-11-17|Saturation of 5-halo-thiazothiazol-3-one-1,1-dioxide derivatives|
    MD94-0300A| MD266C2|1988-02-18|1994-09-14|Process for preparation of 5-haloid thienoisothiazole-3-on-1,1-dioxides derivatives|
    [返回顶部]